CD8A and neoplasm: However, low doses of ROS/RNS in TME derived from in vivo CAP treatment more likely accelerate the exhaustion of tumor-infiltrating CD8+T cells and the immune escape of tumor cells via the PD-1/PD-L1 signaling pathway.